title: Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
abstract: We evaluated transplant-related mortality (TRM), leukaemia relapse, leukaemia-free survival (LFS) and overall survival (OS) in patients receiving busulphan and cyclophosphamide (BuCy) or cyclophosphamide and total body irradiation (CyTBI) prior to allogeneic bone marrow transplantation (BMT) for acute myelogenous leukaemia (AML) in first remission. Outcomes of 381 human leucocyte antigen (HLA)-matched sibling transplants using BuCy were compared with 200 transplants using CyTBI performed between 1988 and 1996. The incidence of hepatic veno-occlusive disease was higher with BuCy (13%) than with CyTBI (6%) (P = 0.009). Risks of acute and chronic GVHD were similar. In multivariate analysis, relapse risk was higher in the BuCy group [relative risk (RR) = 1.72; 95% confidence interval (CI), 1.05-2.81; P = 0.031]. Eleven of 373 evaluable patients in the BuCy group had a central nervous system relapse in contrast to none of 194 evaluable patients in the CyTBI group (P = 0.016). There were no differences in TRM, LFS and OS. CyTBI conditioning may lower relapse risk but produces comparable TRM, LFS and OS to BuCy for HLA-matched sibling transplantation in first remission AML.
authors.affiliation: Mayo Clinic & Foundation, Rochester, MN, USA.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: Waleska S
authors.initials: WS
authors.lastname: Pérez
authors.forename: John P
authors.initials: JP
authors.lastname: Klein
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Bolwell
authors.forename: Bruce
authors.initials: B
authors.lastname: Camitta
authors.forename: Edward A
authors.initials: EA
authors.lastname: Copelan
authors.forename: Robert Peter
authors.initials: RP
authors.lastname: Gale
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Giralt
authors.forename: Armand
authors.initials: A
authors.lastname: Keating
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: David I
authors.initials: DI
authors.lastname: Marks
authors.forename: Philip L
authors.initials: PL
authors.lastname: McCarthy
authors.forename: Carole B
authors.initials: CB
authors.lastname: Miller
authors.forename: Gustavo
authors.initials: G
authors.lastname: Milone
authors.forename: H Grant
authors.initials: HG
authors.lastname: Prentice
authors.forename: James A
authors.initials: JA
authors.lastname: Russell
authors.forename: Kirk R
authors.initials: KR
authors.lastname: Schultz
authors.forename: Michael E
authors.initials: ME
authors.lastname: Trigg
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: Mary M
authors.initials: MM
authors.lastname: Horowitz
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012008:Recurrence; D012042:Registries; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan